ArticlePrion
Introduction: Invited Speakers.
Article in Prion. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Alberta Prion Research Institute, part of Alberta Innovates Bio Solutions, is proud to host the world's largest international prion research congress, PRION 2013: Conquering Frontiers, in Banff, Alberta, Canada from May 26-29, 2013. PRION 2013 will be only the second time this international meeting has been held outside of Europe since it began in 2004. The PRION 2013 International Scientific Advisory Committee includes leading international scholars and policy advisors in both human and animal protein misfolding research from 12 countries: Australia, Brazil, Canada, China, England, France, Germany, Japan, The Netherlands, Scotland, Spain and the United States. Prion and protein misfolding science can inform policy, risk management and mitigation, diagnoses and potential treatments in a range of areas from wildlife management to human dementias and neurodegenerative diseases. Compelling evidence is emerging that prion-like mechanisms may underlie a number of the human neurodegenerative diseases and dementias, providing the opportunity to seek out new treatments and for the cross-fertilization of ideas between the two related fields. This approach will be highlighted at PRION 2013. The theme of PRION 2013 is "Conquering Frontiers." It will be a continuation of the science covered in previous meetings with an emphasis on looking toward investigations in the new frontiers created by the relationships between prion diseases and human neurodegenerative diseases and dementias. The four-day session features scientific talks, workshops and posters on the following themes: Prion and Prion-like Diseases in Humans; Prion Diseases in Animals; Protein Structure and Biology; and Socioeconomic Impacts. The knowledge exchange that will take place at PRION 2013 will help to shape the future of prion and protein misfolding research and its application around the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.